BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28495434)

  • 1. Patterns of recurrence and long-term outcomes in patients who underwent pancreatectomy for intraductal papillary mucinous neoplasms with high grade dysplasia: implications for surveillance and future management guidelines.
    Blackham AU; Doepker MP; Centeno BA; Springett G; Pimiento JM; Malafa M; Hodul PJ
    HPB (Oxford); 2017 Jul; 19(7):603-610. PubMed ID: 28495434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
    Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
    Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The validity of the surgical indication for intraductal papillary mucinous neoplasm of the pancreas advocated by the 2017 revised International Association of Pancreatology consensus guidelines.
    Watanabe Y; Endo S; Nishihara K; Ueda K; Mine M; Tamiya S; Nakano T; Tanaka M
    Surg Today; 2018 Nov; 48(11):1011-1019. PubMed ID: 29961172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.
    Rezaee N; Barbon C; Zaki A; He J; Salman B; Hruban RH; Cameron JL; Herman JM; Ahuja N; Lennon AM; Weiss MJ; Wood LD; Wolfgang CL
    HPB (Oxford); 2016 Mar; 18(3):236-46. PubMed ID: 27017163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
    Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
    Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
    Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
    Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas.
    Hirono S; Yamaue H
    Surg Today; 2020 Jan; 50(1):50-55. PubMed ID: 31807871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series.
    Sahora K; Mino-Kenudson M; Brugge W; Thayer SP; Ferrone CR; Sahani D; Pitman MB; Warshaw AL; Lillemoe KD; Fernandez-del Castillo CF
    Ann Surg; 2013 Sep; 258(3):466-75. PubMed ID: 24022439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
    Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
    Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis.
    Marchegiani G; Mino-Kenudson M; Ferrone CR; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    J Am Coll Surg; 2015 May; 220(5):839-44. PubMed ID: 25840549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are the Current Guidelines for the Surgical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas Adequate? A Multi-Institutional Study.
    Wilson GC; Maithel SK; Bentrem D; Abbott DE; Weber S; Cho C; Martin RC; Scoggins CR; Kim HJ; Merchant NB; Kooby DA; Edwards MJ; Ahmad SA
    J Am Coll Surg; 2017 Apr; 224(4):461-469. PubMed ID: 28088598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance.
    Kang MJ; Jang JY; Lee KB; Chang YR; Kwon W; Kim SW
    Ann Surg; 2014 Aug; 260(2):356-63. PubMed ID: 24378847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Resection for Side-Branch Intraductal Papillary Mucinous Neoplasm (SB-IPMN): a Contemporary Single-Institution Experience.
    Dortch JD; Stauffer JA; Asbun HJ
    J Gastrointest Surg; 2015 Sep; 19(9):1603-9. PubMed ID: 26055134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
    Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas.
    Daudé M; Muscari F; Buscail C; Carrère N; Otal P; Selves J; Buscail L; Bournet B
    World J Gastroenterol; 2015 Mar; 21(9):2658-67. PubMed ID: 25759534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms.
    Frankel TL; LaFemina J; Bamboat ZM; D'Angelica MI; DeMatteo RP; Fong Y; Kingham TP; Jarnagin WR; Allen PJ
    HPB (Oxford); 2013 Oct; 15(10):814-21. PubMed ID: 23782351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with a resected pancreatic mucinous cystic neoplasm have a better prognosis than patients with an intraductal papillary mucinous neoplasm: A large single institution series.
    Griffin JF; Page AJ; Samaha GJ; Christopher A; Bhaijee F; Pezhouh MK; Peters NA; Hruban RH; He J; Makary MA; Lennon AM; Cameron JL; Wolfgang CL; Weiss MJ
    Pancreatology; 2017; 17(3):490-496. PubMed ID: 28416122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Recurrence After Resection of IPMN: Who, When, and How?
    Marchegiani G; Mino-Kenudson M; Ferrone CR; Morales-Oyarvide V; Warshaw AL; Lillemoe KD; Castillo CF
    Ann Surg; 2015 Dec; 262(6):1108-14. PubMed ID: 25793719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas based on a long-term follow-up study: proposals for follow-up strategies.
    Yogi T; Hijioka S; Imaoka H; Mizuno N; Hara K; Tajika M; Tanaka T; Ishihara M; Shimizu Y; Hosoda W; Yatabe Y; Niwa Y; Yoshimura K; Bhatia V; Fujita J; Yamao K
    J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):757-65. PubMed ID: 26148131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.